You’ll find Vernalis listed on the London Stock Exchange under the VER ticker. This area contains investment and shareholder information. Check out the latest share price, see what analysts are saying, review the accounts, and see our presentations and webcasts.

 

  • Listed on the London Stock Exchange
  • Accounts, presentations, analyst reports
  • Regulatory announcements

   

 Vernalis makes regular announcements to the financial community

 Check out the latest presentations for yourself

Presentations and webcasts

 How has Vernalis been doing?

Annual accounts and reports from recent years to download

Financial reports and accounts

Got a question about investing in Vernalis?

Find the answers to commonly asked questions here

FAQs

Get the latest share price, with share price chart and calculator

Plus additional information and services for UK and international shareholders

Shareholder information

Want to see the latest news releases?

From the London Stock Exchange’s regulatory news service

Regulatory announcements

Need to get in touch regarding a Vernalis investment?

Here are the contact details you’ll need

Investor contacts

Latest News

FDA Issues a Complete Response Letter on CCP-08 NDA

Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch